WO1993022336A1 - Improved solubilization and stabilization of factor viii complex - Google Patents
Improved solubilization and stabilization of factor viii complex Download PDFInfo
- Publication number
- WO1993022336A1 WO1993022336A1 PCT/US1993/004045 US9304045W WO9322336A1 WO 1993022336 A1 WO1993022336 A1 WO 1993022336A1 US 9304045 W US9304045 W US 9304045W WO 9322336 A1 WO9322336 A1 WO 9322336A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor viii
- recited
- viii complex
- concentration
- present
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 161
- 230000006641 stabilisation Effects 0.000 title claims abstract description 9
- 238000011105 stabilization Methods 0.000 title claims abstract description 9
- 230000007928 solubilization Effects 0.000 title claims description 17
- 238000005063 solubilization Methods 0.000 title claims description 17
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 151
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 55
- 239000004475 Arginine Substances 0.000 claims abstract description 49
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 239000002904 solvent Substances 0.000 claims abstract description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 37
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 35
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 11
- 239000004471 Glycine Substances 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 229960002897 heparin Drugs 0.000 description 8
- 229920000669 heparin Polymers 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000787 affinity precipitation Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003168 reconstitution method Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
Definitions
- This invention relates to an improved process for solubilizing lyophilized antihemophilic factor (Factor VIII complex) preparations.
- Coagulation of blood is a complex process requiring the sequential interaction of a large number of components, nearly all of which are proteins. These components include fibrinogen and Factors II, V, VII, VIII, IX, X, XI, and XII. A lack of any of these components, or a nonfunctional component, can lead to an inability of the blood to clot when required, with resultant excessive and life-threatening blood loss to the patient.
- Factor VIII is present at deficient levels, or is absent, in certain individuals.
- persons who have a deficiency (or absence) of Factor VIII i.e., persons suffering from hemophilia A, have blood which either fails to clot or clots only after longer periods of time than the time required for clotting in a person who has a normal level of Factor VIII.
- Factor VIII is present in plasma as a high- molecular-weight complex (Factor VIII complex) , which includes Factor VIII:C and von illebrand factor (Factor VIII:R or vWf) .
- Factor VIII:C promotes blood coagulation.
- Factor VIII:R promotes aggregation of platelets and, when incorporated into the Factor VIII complex, acts as a stabilizer for Factor VIII:C.
- Factor VIII complex Purification of the Factor VIII complex has resulted in Factor VIII preparations which have a purity level of about 90% or greater, and which are sufficiently stable for storage for long periods of time in a lyophilized form.
- purity means the amount of the specified protein as a percentage of the total amount of protein in a sample.
- highly-purified, lyophilized Factor VIII complex compositions i.e., compositions with a high Factor VIII:C specific-activity, are difficult to reconstitute in aqueous solutions such as those required for use in intravenous injection.
- the purified solutions require contact with solvents for extended periods of time (about 5-6 min.) before they are resolubilized, and often result in reconstituted solutions which have poor clarity, thus wasting valuable time of hospital employees.
- the reconstituted Factor VIII complex compositions have a limited life, requiring that the reconstituted compositions be discarded after a short period of time. This presents difficulties in the treatment of patients who require injections of Factor VIII complex to maintain blood-clotting ability. Typically, such patients are injected with a dose of about 50 units of Factor VIII:C/kg of body weight about every one to two weeks, although injection schedules vary from person to person depending on the severity of the individual's hemophilia.
- Factor VIII is purified using a two-step PEG precipitation purification scheme, wherein an amino acid or other "salting-in” agent is added to the second PEG precipitation to salt-in contaminants and to give a "sharper" purification of the Factor VIII.
- the salting-in agent used in this method would be substantially removed from the final Factor VIII preparation as a result of the subsequent precipitation of the Factor VIII by PEG.
- the specific-activity of the Factor VIII is limited to only 3.85 to 50 units/mg.
- Factor VIII complex composition which has enhanced solubility in aqueous solutions. It is also desirable that the reconstituted Factor VIII complex is stable at room temperature, so that, once a ⁇ olutior is reconstituted, it can be stored for extended periods of time prior to use.
- a process for producing a lyophilized Factor VIII complex composition which, when reconstituted, exhibits enhanced solubility is described.
- An aqueous solution comprising " a Factor VIII complex preparation incorporating at least 50 units of Factor VIII:C activity per milligram of total protein in the preparation is mixed with a solubilizing agent, comprising arginine, to thereby form a Factor Vlll/arginine solution.
- the Factor VHI/arginine solution is lyophilized to thereby provide a lyophilized Factor VIII composition with enhanced solubility.
- Histidine and human serum albumin may also be added to the solubilizing agent.
- arginine is present at a concentration of about 0.05 M to about 0.5 M, and most preferably from about 0.1 to about 0.2 M, prior to lyophilization.
- Histidine, when added, is present at a concentration of about 0.025 M and the human serum albumin, when added, is present at a concentration of about 0.05% to about 3%, preferably about 0.5%, prior to lyophilization.
- the Factor VIII complex preparation has a specific-activity of about 50 to about 500 units/mg, and the lyophilized Factor VIII complex composition is reconstituted with water at room temperature.
- the process of the present invention provides a simple and efficient method for the preparation of solutions of high specific-activity Factor VIII complex at high concentrations from lyophilized Factor VIII complex compositions. Concentrations of greater than from about 50 units of Factor VIII:C activity/ml are contemplated by the present invention.
- the phrase "high specific-activity" as used herein means a Factor VIII complex preparation having greater than about 50 units of Factor VIII:C activity/mg of protein. While the reconstitution method of the present invention is suitable for use with high concentrations and high specific-activity Factor VIII complex preparations, it is also suitable for use with lower concentrations and lower specific-activity Factor VIII complex preparations.
- the starting material from which the high specific-activity Factor VIII complex product provided in accordance with the present invention is derived may be cryoprecipitate or other blood plasma-derived fractions, or it may be derived by recombinant-DNA or transgenic techniques.
- Factor VIII complex is purified from cryoprecipitate using affinity chromatography and precipitation techniques.
- a key step of the process of the present invention is that the high specific-activity Factor VIII complex, from whatever source, is lyophilized in the presence of a sufficient amount of arginine to enhance its solubility.
- enhanced solubility means the solubility of the Factor VIII complex which has been lyophilized in the presence of the solubilizing agent of the present invention compared to Factor VIII complex which has been lyophilized in the absence of the solubilizing agent of the present invention.
- Other amino acids and/or proteins may be present in addition to arginine.
- the high specific-activity Factor VIII complex is lyophilized in an aqueous solution which includes a solubilizing agent, arginine.
- the solubilizing agent may further comprise histidine and human serum albumin.
- the Factor VIII complex with enhanced solubility is prepared from an aqueous solution comprising from about 0.05 M to about 0.5 M arginine and about 0.1 mg to about 5 mg/ml of Factor VIII complex. When added, histidine and human serum albumin are present at a concentration of about 0.025 M and about 0.05% (wt/vol) to about 3% (wt/vol) , respectively.
- % refers to % weight per volume (wt/vol) , unless otherwise specified.
- the aqueous solution from which the Factor VIII is lyophilized comprises about 0.1 to about 0.2 M arginine, about 0.025 M histidine and about 0.5% (wt/vol) human serum albumin.
- the histidine acts as a buffer. While other buffers may be used, histidine is preferred, since it does not lead to precipitation of the Factor VIII complex or otherwise adversely affect its solubility.
- the arginine acts as a solubilizing agent and aids in the rapid reconstitution of the lyophilized Factor VIII complex.
- the human serum albumin acts as a bulking agent and aids in the long-term stability of the lyophilized Factor VIII complex, once it has been reconstituted.
- the FactorVIII complex/solubilization agent solution is aliquoted into separate vials, each of which is filled with an amount of Factor VIII complex sufficient for at least a single dose of Factor VIII complex.
- the Factor VIII complex composition is then lyophilized to provide a lyophilized Factor VIII composition of enhanced solubility.
- the lyophilized composition may be stored at about 4°C until required for use.
- the lyophilized Factor VIII complex composition When required for use, the lyophilized Factor VIII complex composition, incorporating the solubilization agent, may be readily reconstituted in water or other suitable media.
- the lyophilized Factor VIII complex reconstitutes in water, in less than 1 min. , to provide a solution which has a high degree of clarity and which is stable for extended periods of time at room temperature.
- an aqueous solution comprising about 0.1 to about 5 g/ml of a high specific activity Factor VIII complex preparation, i.e. a Factor VIII complex having an activity of greater than 50 units/mg of Factor VIII:C activity/mg of protein, and arginine is prepared. Histidine and human serum albumin may also be added to the solution.
- the final concentration of the solubilization agent components is about 0.05 M to about 0.5 M arginine, about 0.025 M histidine, and from about 0.05% (wt/vol) to about 3% (wt/vol) human serum albumin.
- the final concentration of the solubilization agent components is about 0.1 M to about 0.2 M arginine, about 0.025 M histidine, and about 0.5% (wt/vol) human serum albumin.
- the solution is then lyophilized and stored at 4°C until required for use.
- the lyophilized Factor VIII complex is dissolved in distilled water or a suitable buffer solution.
- the present invention could be practiced with any Factor VIII complex purification procedure which results in the preparation of Factor VIII complex of a high specific-activity.
- Example 1 Preparation of Purified Factor VIII Complex 9,030 kg of plasma were cryoprecipitated by freezing the plasma at a temperature of about -20°C, and is subsequently thawed at 0°C to 5°C.
- the 107 kg of cryoprecipitate which forms during the thawing process was collected and dissolved in 320 liters (1) of distilled water containing about 120 units of heparin per ml of water.
- the heparin solution was mixed at a temperature of 30°C until the cryoprecipi ⁇ tate was completely dissolved (approximately 10 min.) , to provide a cryoprecipitate/heparin solution.
- the pH of the cryoprecipitate /heparin solution was adjusted to about 7, using 0.1 M HC1, and the solution was stirred for an additional 20 to 30 min.
- aqueous PEG solution comprising 31.5% (wt/vol) PEG, 0.22% (wt/vol) sodium citrate dihydrate, and 0.08% (wt/vol) citric acid monohydrate, at a pH of 6.2, was then added to the cryoprecipitate/heparin solution, to give a final concentration of 3.5% (wt/vol) PEG.
- the pH of the PEG/cryoprecipitate/heparin solution was adjusted to 6.3 with dilute acetic acid.
- the pH- adjusted solution was mixed for approximately 15 min. , at a temperature of 27°C.
- the addition of PEG resulted in precipitation of various contaminating proteins from the Factor VIII complex, which remained in solution.
- the PEG precipitate was separated from the Factor VIII complex-containing supernatant solution by centri- fugation.
- the PEG supernatant i.e., the Factor VIII complex containing impure protein fraction, was recovered.
- the supernatant was then treated to inactivate viruses which may be present in the blood products, by the addition of a solution containing 0.3% (wt/vol) tri-n-butylphosphate and 1% (wt/vol) TWEEN-80 and incubating at 25°C for 6 hrs.
- the viral-inactivated supernatant solution i.e., the viral-inactivated Factor VIII complex containing impure protein fraction
- the viral-inactivated supernatant solution was clarified by filtration and then recovered for further purification of Factor VIII complex by affinity chromatography on a heparin- coupled chromatographic medium.
- the Factor VIII complex-containing solution was applied to a 200 liter (1) heparin-coupled chromatographic medium packed into the column.
- the column effluent was collected, and the column was washed with 1700 1 of 0.025 M histidine, pH 6.8, containing 0.10 M NaCl.
- Elution of Factor VIII complex was achieved with 600 1 of 0.1 M CaCl 2 and 0.025 M histidine, pH 6.8.
- the eluate from a heparin column was concentrated 15-fold using a CENTRASETTE, Omega 100K cassette.
- the concentrated solution i.e., the eluate concentrate, was then brought to 2 M glycine and 1.2 M NaCl and mixed at 25°C for 2 hours.
- the precipitate which formed was collected by centrifugation and washed with a wash solution comprising 0.025 M histidine, pH 6.8, 2 M glycine, and 1.3 M NaCl.
- the washed precipitate was collected by filtration.
- a sample of the washed precipitate was dissolved in a buffer comprising 0.025 M histidine, 0.1 M arginine, pH 7.0 to 7.6, to a concentration of 0.5 mg of Factor VIII complex/ml of buffer.
- IgG ( ⁇ g/unit) ⁇ 0.1
- the combinations 0.1 M arginine, 0.025 M histidine; 0.1 M arginine, 0.025 M histidine, 0.5% (wt/vol) human serum albumin; 0.28 M arginine, 0.025 M histidine; and 0.28 M arginine, 0.025 M histidine, and 0.5% (wt/vol) human serum albumin are effective as agents to enhance the resolubilization of lyophilized Factor VIII complex.
- the sample was divided into two portions. One portion was brought to 0.1 M arginine and 0.5% (wt/vol) human serum albumin by the addition of arginine and human serum albumin. The other portion was broug. to 0.1 M glycine and 0.5% (wt/vol) human serum albumin by the addition of glycine and human serum albumin.
- the samples were then lyophilized. Each of the lyophilized preparations was then reconstituted in water, to give a Factor VIII complex concentration of 3 mg/ml, and the samples were incubated at room temperature for up to 22 days. Each of the reconstituted Factor VIII complex solutions was sampled periodically and assayed for Factor VIII:C activity. The results are summarized in Table V.
- HSA Human Serum Albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93910911A EP0638091B1 (en) | 1992-04-30 | 1993-04-29 | Improved solubilization and stabilization of factor viii complex |
AU42238/93A AU670793B2 (en) | 1992-04-30 | 1993-04-29 | Improved solubilization and stabilization of factor VIII complex |
DE69333928T DE69333928T2 (en) | 1992-04-30 | 1993-04-29 | IMPROVED SOLUBILIZATION AND STABILIZATION OF THE FACTOR VIII COMPLEX |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87619092A | 1992-04-30 | 1992-04-30 | |
US07/876,190 | 1992-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993022336A1 true WO1993022336A1 (en) | 1993-11-11 |
Family
ID=25367170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/004045 WO1993022336A1 (en) | 1992-04-30 | 1993-04-29 | Improved solubilization and stabilization of factor viii complex |
Country Status (5)
Country | Link |
---|---|
US (1) | US5399670A (en) |
EP (1) | EP0638091B1 (en) |
AU (1) | AU670793B2 (en) |
DE (1) | DE69333928T2 (en) |
WO (1) | WO1993022336A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10509144A (en) * | 1994-11-14 | 1998-09-08 | フアーマシア・アンド・アツプジヨン・アー・ベー | (VIII) Factor purification method |
US6579723B1 (en) | 1997-02-27 | 2003-06-17 | Baxter Aktiengesellschaft | Method of recovering highly purified vWF or factor VIII/vWF-complex |
US6887852B1 (en) * | 2004-06-25 | 2005-05-03 | Korea Green Cross Corporation | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer |
US8372800B2 (en) | 1999-02-22 | 2013-02-12 | Baxter International Inc. | Albumin-free factor VIII formulations |
US10238718B2 (en) | 2014-08-04 | 2019-03-26 | Csl Limited | Factor VIII formulation |
US10512674B2 (en) | 2008-11-07 | 2019-12-24 | Baxalta Incorporated | Factor VIII formulations |
WO2023017020A1 (en) * | 2021-08-11 | 2023-02-16 | Grifols Worldwide Operations Limited | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained |
WO2023119277A1 (en) * | 2021-12-21 | 2023-06-29 | Omrix Biopharmaceuticals Ltd. | Highly soluble fibrinogen compositions |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5847086A (en) * | 1991-06-20 | 1998-12-08 | Centeon L.L.C. | Therapeutic fragments of von Willebrand factor |
IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5659017A (en) * | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
JP2000509374A (en) * | 1996-04-19 | 2000-07-25 | アルファ セラピュティック コーポレイション | Method for virus inactivation of lyophilized blood proteins |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
US7282219B2 (en) * | 2000-03-31 | 2007-10-16 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
JP4340062B2 (en) * | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | Concentrated protein preparation with reduced viscosity |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US20020146409A1 (en) * | 2001-01-30 | 2002-10-10 | Herring Steven W. | Methods for stabilizing lyophilized blood proteins |
BR0215216A (en) | 2001-12-21 | 2004-11-16 | Novo Nordisk Healthcare Ag | Liquid aqueous composition, method for preparing a liquid aqueous composition of a factor vii polypeptide, use of a liquid aqueous composition, and method for treating a factor vii response syndrome |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
PT2283856T (en) * | 2002-06-21 | 2017-12-26 | Novo Nordisk Healthcare Ag | Stabilised solid compositions of factor viia polypeptides |
US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
ES2609010T3 (en) | 2003-04-04 | 2017-04-18 | Genentech, Inc. | Antibody and protein formulations at high concentration |
WO2004103398A1 (en) * | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
DE602004023848D1 (en) * | 2003-07-01 | 2009-12-10 | Novo Nordisk Healthcare Ag | OF FACTOR VII POLYPEPTIDES |
FR2857267B1 (en) * | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | STABILIZING AND SOLUBILIZING FORMULATION FOR CRYOPRECIPITABLE PROTEINS. |
WO2005016365A2 (en) | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
ES2229931B1 (en) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX. |
TR201809670T4 (en) * | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Stabilized compositions of factor VII polypeptides. |
US7572893B2 (en) * | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
PT2586459T (en) | 2005-03-25 | 2017-07-25 | Regeneron Pharma | Vegf antagonist formulations |
FR2894831B1 (en) * | 2005-12-16 | 2008-02-15 | Lab Francais Du Fractionnement | THROMBIN FREE BIOLOGICAL GLUE AND USE THEREOF AS MEDICAMENT. |
SI2944306T1 (en) | 2006-06-16 | 2021-04-30 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
EP2403874A1 (en) * | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
SI2440239T1 (en) | 2009-06-09 | 2018-01-31 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
RU2603481C2 (en) | 2011-01-28 | 2016-11-27 | Санофи Байотекнолоджи | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
EP2704688B1 (en) * | 2011-05-05 | 2019-07-10 | Matinas BioPharma Nanotechnologies, Inc. | Cochleate compositions and methods of making and using same |
AR087305A1 (en) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT |
WO2013039969A1 (en) | 2011-09-16 | 2013-03-21 | Regeneron Pharmaceuticals, Inc. | METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
AU2013212587B2 (en) | 2012-01-23 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
KR20240017117A (en) | 2014-07-16 | 2024-02-06 | 사노피 바이오테크놀로지 | METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA(heFH) |
LT3170005T (en) | 2014-07-18 | 2019-07-10 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
EP3337828A1 (en) | 2015-08-18 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
WO2019074886A1 (en) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
EP3937878A2 (en) | 2019-03-14 | 2022-01-19 | Terumo BCT Biotechnologies, LLC | Lyophilization loading tray assembly and system |
KR20220029733A (en) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII |
FR3112284B1 (en) | 2020-07-10 | 2024-02-09 | Vaxinano | METHOD FOR PREPARING A VACCINE COMPOSITION FROM FREEZE-DRIED ANTIGENS |
CN116322920A (en) | 2020-11-09 | 2023-06-23 | 武田药品工业株式会社 | Purification of FVIII from plasma using silica adsorption |
WO2022218962A1 (en) | 2021-04-13 | 2022-10-20 | Grifols Worldwide Operations Limited | Liquid composition comprising factor viii or factor viii/von willebrand factor complex |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4650858A (en) * | 1983-03-21 | 1987-03-17 | Nordisk Gentofte A/S | Concentrate of the antihemophilic factor VIII and a process for producing it |
US4758657A (en) * | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3203775A1 (en) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | FIBRINOGEN PREPARATION, METHOD FOR THEIR PRODUCTION AND THEIR USE |
JPS6122022A (en) * | 1983-12-28 | 1986-01-30 | Green Cross Corp:The | Method for heat-treating blood plasma protein |
CA1329760C (en) * | 1987-10-29 | 1994-05-24 | Ted C. K. Lee | Plasma and recombinant protein formulations in high ionic strength media |
US5110907A (en) * | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
-
1993
- 1993-04-29 EP EP93910911A patent/EP0638091B1/en not_active Expired - Lifetime
- 1993-04-29 WO PCT/US1993/004045 patent/WO1993022336A1/en active IP Right Grant
- 1993-04-29 AU AU42238/93A patent/AU670793B2/en not_active Expired
- 1993-04-29 DE DE69333928T patent/DE69333928T2/en not_active Expired - Lifetime
- 1993-04-29 US US08/054,903 patent/US5399670A/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4650858A (en) * | 1983-03-21 | 1987-03-17 | Nordisk Gentofte A/S | Concentrate of the antihemophilic factor VIII and a process for producing it |
US4758657A (en) * | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10509144A (en) * | 1994-11-14 | 1998-09-08 | フアーマシア・アンド・アツプジヨン・アー・ベー | (VIII) Factor purification method |
US6579723B1 (en) | 1997-02-27 | 2003-06-17 | Baxter Aktiengesellschaft | Method of recovering highly purified vWF or factor VIII/vWF-complex |
US9352027B2 (en) | 1999-02-22 | 2016-05-31 | Baxalta Incorporated | Albumin-free factor VIII formulations |
US9669076B2 (en) | 1999-02-22 | 2017-06-06 | Baxalta Incorporated | Albumin-free factor VIII formulations |
US8372800B2 (en) | 1999-02-22 | 2013-02-12 | Baxter International Inc. | Albumin-free factor VIII formulations |
US8765665B2 (en) | 1999-02-22 | 2014-07-01 | Baxter International Inc. | Albumin-free factor VIII formulations |
EP1712223A1 (en) * | 2004-06-25 | 2006-10-18 | Green Cross Holdings | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer |
US6887852B1 (en) * | 2004-06-25 | 2005-05-03 | Korea Green Cross Corporation | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer |
US10512674B2 (en) | 2008-11-07 | 2019-12-24 | Baxalta Incorporated | Factor VIII formulations |
US11020459B2 (en) | 2008-11-07 | 2021-06-01 | Baxalta Incorporated | Factor VIII formulations |
US10238718B2 (en) | 2014-08-04 | 2019-03-26 | Csl Limited | Factor VIII formulation |
WO2023017020A1 (en) * | 2021-08-11 | 2023-02-16 | Grifols Worldwide Operations Limited | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained |
WO2023119277A1 (en) * | 2021-12-21 | 2023-06-29 | Omrix Biopharmaceuticals Ltd. | Highly soluble fibrinogen compositions |
Also Published As
Publication number | Publication date |
---|---|
DE69333928D1 (en) | 2006-01-12 |
AU670793B2 (en) | 1996-08-01 |
AU4223893A (en) | 1993-11-29 |
EP0638091A4 (en) | 1996-04-17 |
EP0638091A1 (en) | 1995-02-15 |
EP0638091B1 (en) | 2005-12-07 |
DE69333928T2 (en) | 2006-08-17 |
US5399670A (en) | 1995-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0638091B1 (en) | Improved solubilization and stabilization of factor viii complex | |
US4877608A (en) | Pharmaceutical plasma protein formulations in low ionic strength media | |
CA1329760C (en) | Plasma and recombinant protein formulations in high ionic strength media | |
US5605884A (en) | Factor VIII formulations in high ionic strength media | |
EP0627924B1 (en) | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer | |
CA2378751C (en) | Stable factor viii compositions | |
EP0378208B1 (en) | Production method for protein-containing composition | |
US4203891A (en) | Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin | |
US9938318B2 (en) | Process for production of fibrinogen | |
JPH0597702A (en) | Stabilized viii factor preparation | |
JPS597693B2 (en) | Antithrombin preparation and its manufacturing method | |
JPS596845B2 (en) | Method for improving yield of antihemophilic factor | |
HU215098B (en) | Process for large scale production of high purity, pharmaceutically applicable, standardized human von willebrand factor concentrate | |
CA2282841C (en) | A method of purifying factor viii/vwf-complex by means of cation exchange chromatography | |
US5484890A (en) | Antihemophilic factor stabilization | |
US4379085A (en) | Heat stabilization of plasma proteins | |
EP0148843B2 (en) | A concentrate of the antihemophilic factor viii and a process for producing it | |
JPH0676337B2 (en) | Method for producing high-purity antihemophilic factor concentrate | |
EP0245875A2 (en) | Method of purifying factor VIII | |
EP0449897B1 (en) | A pure factor i protein and a process for producing said protein | |
Ng et al. | Preparation of high purity factor VIII concentrates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993910911 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993910911 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993910911 Country of ref document: EP |